INTRODUCTION
============

The emergence of carbapenemase-producing *Enterobacteriaceae* (CPE) is a major clinical concern because these bacteria are resistant to multiple classes of antibiotics, which can lead to therapeutic failure \[[@B1]\]. CPE produce enzymes that fall into three classes according to the Ambler classification: class A β-lactamases (*Klebsiella pneumoniae* carbapenemase \[KPC\]), class B metallo-β-lactamases (New Delhi metallo-β-lactamase \[NDM\], imipenemase \[IMP\], and Verona integron-encoded metallo-β-lactamase \[VIM\]), and class D β-lactamases (oxacillinase \[OXA\]-48). The carbapenemase genes in *Enterobacteriaceae* have been shown to be associated with mobile genetic elements such as plasmids or transposons, thereby facilitating infection outbreaks \[[@B2]\].

The first strain of KPC-producing *K. pneumoniae* was identified in North Carolina, USA, in 1996 \[[@B3]\]. Several outbreaks associated with these strains have been reported in the USA, South America, Europe, and China \[[@B4]\]. After the first identification of an OXA-48-producing *K. pneumoniae* strain in Istanbul, Turkey, in 2001 \[[@B5]\], numerous outbreaks caused by strains like OXA-48 have been reported in Europe, the Indian subcontinent, the Middle East, and Northern Africa \[[@B6]\]. In the present study, we report the prevalence and molecular epidemiology of CPE isolates collected from five university hospitals in Korea in 2015.

METHODS
=======

1. Study design
---------------

From January to December 2015, five university hospitals in a central province (two hospitals in Seoul, two hospitals in Gyeonggi, and one hospital in Gangwon) of Korea collected prospectively ertapenem-nonsusceptible *Enterobacteriaceae* isolates including species such as *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter cloacae*, *Enterobacter aerogenes*, *Serratia marcescens*, and *Citrobacter freundii* by means of a Vitek 2 (bioMérieux Vitek, Hazelwood, MO, USA) or MicroScan system (Siemens, Sacramento, CA, USA). The isolates were included in the study, if they were not susceptible to ertapenem (minimal inhibitory concentration \[MIC\] \>0.5 µg/mL) \[[@B7]\]. This study protocols was approved by the Institutional Review Board of each institution, which decided to waive the informed consent.

2. Genotypic detection of β-lactamase genes
-------------------------------------------

All ertapenem-nonsusceptible isolates were tested for carbapenemase by multiplex PCR. The carbapenemase gene was detected by PCR primers encompassing the entire coding region of genes *bla*~KPC~, *bla*~NDM~, *bla*~IMP~, *bla*~VIM~, *bla*~GES~, and *bla*~OXA-48~ \[[@B8]\]. All carbapenemase-positive isolates were tested for extended-spectrum β-lactamase (ESBL) and plasmid-mediated AmpC genes by PCR according to previously described methods \[[@B9][@B10]\]. All PCR products were directly sequenced with an automatic sequencer (model 373*xl*; Applied Biosystems, Weiterstadt, Germany).

3. Antimicrobial susceptibility testing
---------------------------------------

Antimicrobial susceptibility was tested in two hospitals that experienced an outbreak for 24 KPC-2 *K. pneumoniae* in hospital B and 45 OXA-232 *K. pneumoniae* in hospital C. The MICs of the CPE isolates were determined by using an Etest (bioMérieux, Marcy-I\'Etoile, France). The antimicrobial agents tested were: cefotetan, cefotaxime, ceftazidime, cefepime, aztreonam, ertapenem, imipenem, meropenem, amikacin, ciprofloxacin, tigecycline, and colistin. When available, the MIC results were interpreted according to the CLSI criteria, 2014 \[[@B7]\]. For tigecycline and colistin, the European Committee for Antimicrobial Susceptibility Testing (EUCAST) criteria (<http://www.eucast.org/clinical_breakpoints>, January 2014) were used.

4. Molecular typing by pulsed-field gel electrophoresis (PFGE)
--------------------------------------------------------------

Genetic relatedness of KPC-2 *K. pneumoniae* and OXA-232 *K. pneumoniae* isolates was collectively evaluated by PFGE at one time. Plugs containing *Xba*I-digested genomic DNA were prepared, and DNA fragments were separated for 20 hr at 6 V/cm at 11℃ on a CHEF-DRII System (Bio-Rad, Hercules, CA, USA) with initial and final pulse times of 0.5 sec and 30 sec, respectively. A lambda ladder (Bio-Rad) was used as a DNA size marker. Gels with PFGE-separated fragments of chromosomal DNA were blotted onto nylon membranes (Bio-Rad) and hybridized with probes by using the DIG DNA Labeling and Detection Kit (Roche Diagnostics GmbH, Mannheim, Germany). Similarity coefficients were calculated from Dice coefficients. Cluster analysis was conducted by the unweighted pair group method with arithmetic averages (UPGMA). Isolates that had a PFGE profile with more than 90% similarity (pulsotype \[PT\]) were considered closely related strains.

5. Patient characteristics
--------------------------

The clinical characteristics collected from patients who contracted KPC-2 *K. pneumoniae* and OXA-232 *K. pneumoniae* isolates were age, sex, sampling date, isolation site, hospitalization ward, hospitalization days, and in-hospital death by reviewing the medical records.

6. Statistical analysis
-----------------------

All calculations were performed using R software, version 3.2.4 (R Development Core Team 2016; <http://www.R-project.org/>). Categorical variables were compared by Chi-square test or Fisher\'s exact test, and continuous variables were compared by Student\'s t-test. All tests were two-sided, and differences with *P* value ≤0.05 were considered significant.

RESULTS
=======

1. Distribution of CPE isolates
-------------------------------

Between January and December 2015, 393 (3.0% of all 13,005 *Enterobacteriaceae* isolates) ertapenem-nonsusceptible, non-duplicated isolates were collected. These 393 isolates were 177 *K. pneumoniae* isolates (45.0%), 108 *Enterobacter cloacae* isolates (27.5%), 46 *S. marcescens* isolates (11.7%), 36 *Escherichia coli* isolates (9.2%), 21 *Enterobacter aerogenes* isolates (5.3%), and five *C. freundii* isolates (1.3%) ([Table 1](#T1){ref-type="table"}).

The distribution of different carbapenemases among the *Enterobacteriaceae* isolates is summarized in [Table 2](#T2){ref-type="table"}. Carbapenemases were responsible for resistance in 79 isolates (0.6% of all 13,005 *Enterobacteriaceae*, 20.1% of all 393 ertapenem-resistant *Enterobacteriaceae*). Among the 79 CPE isolates, 47 (59.5%), 27 (34.2%), 4 (5.1%), and 1 (1.2%) were OXA-232, KPC-2, IMP-1, and NDM-1 producers, respectively. All CPE isolates co-produced ESBLs; for example, KPC-2 *K. pneumoniae* isolates also had CTX-M-65, and OXA-232 *K. pneumoniae* isolates also had CTX-M-15. The most prevalent species among the OXA-232 and the KPC-2 strains were *K. pneumoniae* (89.8%: OXA-232 at 58.2% and KPC-2 at 31.6%). Two hospitals experienced an outbreak (hospital B: KPC-2 *K. pneumoniae*, hospital C: OXA-232 *K. pneumoniae*), and no CPE were isolated in hospital D.

2. Patient characteristics
--------------------------

Fifty-three patients (76.8%) were male. The mean age of the patients was 64.6 yr. The following specimens were provided: respiratory secretions (n=31, 44.9%), urine (n=17, 24.6%), wound or pus (n=9, 13.1%), and blood (n=5, 7.3%). No CPE was isolated from outpatients. Forty-nine percent (n=34) of isolates were from patients in intensive care units (ICU). All isolates were collected from patients after more than two days of hospitalization. The median number of hospitalization days before CPE isolation from the patients with KPC-2 and OXA-232 isolates was 40 and 16 days (*P*=0.006), respectively. Twenty-eight percent (n=19) of patients died during hospitalization ([Table 3](#T3){ref-type="table"}).

3. Antimicrobial susceptibilities
---------------------------------

One-hundred percent and 92% of KPC-2 *K. pneumoniae* isolates were susceptible to tigecycline and colistin, respectively, while 100% were resistant to all cephalosporins, aztreonam, carbapenems, amikacin, and ciprofloxacin. Seventy-eight percent and 89% of OXA-232 *K. pneumoniae* isolates were susceptible to tigecycline and colistin, respectively. More than 90% of them were resistant to all cephalosporins, aztreonam, ertapenem, meropenem, and ciprofloxacin, but the imipenem resistance rate was 69% ([Table 4](#T4){ref-type="table"}).

4. Pulsed-field gel electrophoresis typing
------------------------------------------

Of the 24 KPC-2 *K. pneumoniae* and 45 OXA-232 *K. pneumoniae* isolates, 61 were available for PFGE. This analysis revealed a unique pattern for 20 KPC-2 *K. pneumoniae* isolates in hospital B ([Fig. 1](#F1){ref-type="fig"}). PFGE of 41 OXA-232 *K. pneumoniae* isolates from hospital C identified seven PTs, of which 21 isolates belonged to the dominant PT1, and nine were PT2 ([Fig. 2](#F2){ref-type="fig"}).

DISCUSSION
==========

Until now, the carbapenem resistance rate among *Enterobacteriaceae* isolates from Korea has been relatively low and stable \[[@B11]\]. The present study showed that the incidence of ertapenem-nonsusceptible *Enterobacteriaceae* is 3% and the incidence of CPE is 0.6% (out of 13,005 isolates) of *Enterobacteriaceae* and 20.1% (out of 383 isolates) of ertapenem-nonsusceptible *Enterobacteriaceae*. The most common CPE organism was *K. pneumoniae* (92.4%). The overall incidence of carbapenem-resistant *Enterobacteriaceae* (CRE) in the USA is estimated to be 1.4% to 4.2% \[[@B12]\]. CPE have been detected in 81.7% and 20% of CRE isolates in the USA \[[@B13]\] and Taiwan \[[@B14]\], respectively.

Three main carbapenemases are reported worldwide: KPC, NDM, and OXA-48-like. KPC strains are mostly found in the USA, Israel, Greece, and Italy. The Indian subcontinent is recognized as an NDM and OXA-48-like endemic zone. OXA-48-like is often seen in the Mediterranean area and Northern Africa \[[@B4]\]. OXA-162, -163, -181, -204, and -232 were identified as OXA-48 variants \[[@B6]\]. Korea is known for outbreaks of *K. pneumoniae* that produce KPC-2, NDM-1, and OXA-232 \[[@B15][@B16][@B17]\]. In the present study, two of five hospitals had an outbreak (hospital B: KPC-2 *K. pneumoniae*, hospital C: OXA-232 *K. pneumoniae*), and no CPE were isolated in one hospital. All CPE isolates co-produced ESBLs: mainly CTX-M-65 and CTX-M-15.

Most patients in this study were older male inpatients, and the most common specimens analyzed were respiratory secretions and urine. These findings are similar to the results of other studies \[[@B14][@B18][@B19]\]. The median number of hospitalization days before CPE isolation among the patients with these isolates was 17 days, and the median number of hospitalization days of patients with KPC-2 isolates was 40 days. Long-term hospitalization may play an important role in the spread of CPE. This study excluded analysis of infection and colonization with CPE because it was hard to distinguish some cases retrospectively.

In this study, all KPC-2 *K. pneumoniae* isolates were highly resistant to all cephalosporins, aztreonam, and carbapenems. More than 90% of OXA-232 *K. pneumoniae* isolates were resistant to all cephalosporins, aztreonam, ertapenem, and meropenem. The likely reason is that all OXA-232 *K. pneumoniae* isolates also produce ESBLs. OXA-48 hydrolyzes penicillins effectively, but it only weakly hydrolyzes carbapenems. In addition, this enzyme shows very weak activity toward extended-spectrum cephalosporins \[[@B20]\]. OXA-48-like producers that do not produce any ESBLs are still susceptible to broad-spectrum cephalosporins and can be susceptible or resistant to carbapenems \[[@B6]\]. Only tigecycline and colistin remained effective against most, but not all, KPC-2 and OXA-232 *K. pneumoniae* isolates.

The PFGE analysis revealed a unique pattern for 20 KPC-2 *K. pneumoniae* and 41 OXA-232 *K. pneumoniae* isolates, of which 21 isolates belonged to the dominant PT1, and nine were PT2. These findings highlighted the risk of clonal dissemination of KPC-2 *K. pneumoniae* and OXA-232 *K. pneumoniae* in certain wards, especially in ICUs.

In summary, CPE strains are present in Korea, with the main *K. pneumoniae* isolates producing OXA-232 and KPC-2. Interestingly, the prevalence and predominant genotypes of CPE in Korea showed hospital-specific differences such as epidemic presence in two hospitals, sporadic presence in two hospitals, and absence in one hospital. These findings indicate that CPE dissemination is at an early stage in Korea. Therefore, greater efforts to control the nosocomial spread of CPE are warranted. Our results were based on isolates from five university hospitals. Among the strains, most were derived from two hospitals. This situation does not reflect the general epidemiology of CPE in Korea; hence, further large-scale research including isolates from acute care and long-term care hospitals is needed.
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![Pulsed-field gel electrophoresis (PFGE) patterns of KPC-2-producing *K. pneumoniae* isolated in hospital B (n=20). Isolates that exhibited PFGE dendrograms with more than 90% similarity were considered as one pulsotype (PT).](alm-36-529-g001){#F1}

![Pulsed-field gel electrophoresis (PFGE) patterns of OXA-232-producing *K. pneumoniae* isolated in hospital C (n=41). Isolates that exhibited PFGE dendrograms with more than 90% similarity were considered as one pulsotype (PT). Black line in dendrogram represents percentage similarity cut-off.](alm-36-529-g002){#F2}

###### Ertapenem susceptibility of *Enterobacteriaceae* isolates as determined by commercial broth microdilution systems^\*^

![](alm-36-529-i001)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Hospital   N (%) of isolates                                                                                                                                                                    
  ---------- ------------------- ------- ------- -------- ------- ------- -------- ------- -------- -------- ------- ------- -------- ------- -------- -------- ------- ------- --------- ------- -------
  A          1,501\              0\      2\      623\     2\      16\     96\      6\      30\      116\     0\      9\      101\     0\      23\      43\      0\      1\      2,480\    8\      81\
             (99.9)              (0)     (0.1)   (97.2)   (0.3)   (2.5)   (72.7)   (4.6)   (22.7)   (92.8)   (0)     (7.2    (81.5)   (0)     (18.5)   (97.7)   (0)     (2.3)   (96.5)    (0.3)   (3.2)

  B          1,273\              5\      2\      393\     7\      28\     120\     13\     7\       104\     2\      3\      72\      0\      3\       52\      0\      0\      2,014\    27\     43\
             (99.4)              (0.4)   (0.2)   (91.8)   (1.7)   (6.5)   (85.7)   (9.3)   (5.0)    (95.4)   (1.8)   (2.8)   (96.0)   (0)     (4.0)    (100)    (0)     (0)     (96.6)    (1.3)   (2.1)

  C          2,251\              0\      9\      729\     5\      81\     139\     0\      29\      159\     0\      2\      85\      0\      16\      83\      0\      2\      3,446\    5\      139\
             (99.6)              (0)     (0.4)   (89.5)   (0.6)   (9.9)   (82.7)   (0)     (17.3)   (98.8)   (0)     (1.2)   (84.2)   (0)     (15.8)   (97.6)   (0)     (2.4)   (96.0)    (0.1)   (3.9)

  D          1,900\              7\      4\      507\     3\      1\      117\     2\      12\      149\     0\      3\      41\      2\      1\       40\      0\      1\      2,754\    14\     22\
             (99.4)              (0.4)   (0.2)   (99.2)   (0.6)   (0.2)   (89.3)   (1.5)   (9.2)    (98.0)   (0)     (2.0)   (93.2)   (4.5)   (2.3)    (97.6)   (0)     (2.4)   (98.7)    (0.5)   (0.8)

  E          1,206\              2\      5\      517\     4\      30\     59\      2\      7\       73\      0\      2\      18\      0\      1\       45\      1\      0\      1,918\    9\      45\
             (99.4)              (0.2)   (0.4)   (93.9)   (0.7)   (5.4)   (86.8)   (2.9)   (10.3)   (97.3)   (0)     (2.7)   (94.7)   (0)     (5.3)    (97.8)   (2.2)   (0)     (97.3)    (0.4)   (2.3)

  Total      8,131\              14\     22\     2,769\   21\     156\    531\     23\     85\      601\     2\      19\     317\     2\      44\      263\     1\      4\      12,612\   63\     330\
             (99.5)              (0.2)   (0.3)   (94.0)   (0.7)   (5.3)   (83.1)   (3.6)   (13.3)   (96.6)   (0.3)   (3.1)   (87.3)   (0.6)   (12.1)   (98.1)   (0.4)   (1.5)   (97.0)    (0.5)   (2.5)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Isolated from hospital A, C, D, and E were tested with the Vitek 2 system, and those from hospital B were tested with the MicroScan system.

Abbreviations: S, susceptible; I, intermediate; R, resistant.

###### Distribution of carbapenemase-producing *Enterobacteriaceae* isolates per hospital

![](alm-36-529-i002)

  Carbapenemase   Organism          N of carbapenemase-producing *Enterobacteriaceae* isolates^\*^                     
  --------------- ----------------- ---------------------------------------------------------------- ---- ---- --- --- ----
  OXA-232         *K. pneumoniae*   0                                                                0    45   0   1   46
  *E. coli*       0                 0                                                                1    0    0   1   
  KPC-2           *K. pneumoniae*   0                                                                24   0    0   1   25
  *E. coli*       1                 0                                                                0    0    0   1   
  *E. cloacae*    1                 0                                                                0    0    0   1   
  IMP-1           *K. pneumoniae*   0                                                                0    0    0   2   2
  *E. cloacae*    0                 0                                                                2    0    0   2   
  NDM-1           *E. coli*         0                                                                0    1    0   0   1
  Total                             2                                                                24   49   0   4   79

^\*^1 KPC-2 *E. coli* harbored SHV-12 + CTX-M-65, 1 KPC-2 *E. cloacae* harbored CTX-M-15 (hospital A); 24 KPC-2 *K. pneumoniae* harbored CTX-M-65 (hospital B); 45 OXA-232 *K. pneumoniae* harbored 42 CTX-M 15, 1 SHV-2, 1 SHV-12, and 1 SHV-38, respectively, 1 OXA-232 *E. coli* harbored CTX-M-15, 2 IMP-1 *E. cloacae* harbored CTX-M-14, 1 NDM-1 *E. coli* harbored CTX-M-15 (hospital C); 1 OXA-232 *K. pneumoniae* harbored CTX-M-15, 1 KPC-2 *K. pneumoniae* harbored SHV-12 + CTX-M-15, 2 IMP-1 *K. pneumoniae* harbored 1 SHV-12 and 1 SHV-12+CTX-M-15, respectively (hospital E).

Abbreviations: OXA, oxacillinase; KPC, *Klebsiella pneumoniae* carbapenemase; IMP, imipenemase; NDM, New Delhi metallo-β-lactamase.

###### Clinical characteristics of patients with KPC-2-producing *K. pneumoniae* and OXA-232-producing *K. pneumoniae* isolates

![](alm-36-529-i003)

  Characteristic                            N (%) of patients   *P* values                  
  ----------------------------------------- ------------------- ------------- ------------- -------
  Age (mean ± SD)                           64.6 ± 11.8         66.9 ± 8.6    63.4 ± 13.1   0.189
  Male gender                               53 (76.8)           19 (79.2)     34 (75.6)     0.969
  Specimen                                                                                  0.059
   Respiratory                              31 (44.9)           6 (25.0)      25 (55.6)     
   Urine                                    17 (24.6)           8 (33.4)      9 (20.0)      
   Wound or pus                             9 (13.1)            6 (25.0)      3 (6.7)       
   Blood                                    5 (7.3)             2 (8.3)       3 (6.7)       
   Others                                   7 (10.1)            2^\*^ (8.3)   5^†^ (11.0)   
  ICU hospitalization                       34 (49.3)           11 (45.8)     23 (51.1)     0.869
  Hospitalization days \[median (range)\]                                                   
   Before CPE isolation                     17 (1--187)         40 (2--142)   16 (1--187)   0.006
   After CPE isolation                      21 (1--132)         30 (3--124)   12 (1--132)   0.142
  Died during hospitalization               19 (27.5)           5 (20.8)      14 (31.1)     0.486

^\*^These two isolates were recovered from bile juice; ^†^These five isolates were recovered from catheter tips (n=3), ascites (n=1), and bile juice (n=1).

Abbreviations: KPC, *Klebsiella pneumoniae* carbapenemase; OXA, oxacillinase; ICU, intensive care unit; CPE, carbapenemase-producing *Enterobacteriaceae*.

###### Antimicrobial susceptibility of carbapenemase-producing *K. pneumoniae* isolates

![](alm-36-529-i004)

  Antimicrobial agent   KPC-2-producing *K. pneumoniae* isolates (n=24)   OXA-232-producing *K. pneumoniae* isolates (n = 45)                                                        
  --------------------- ------------------------------------------------- ----------------------------------------------------- -------- ----- ------------------- -------- -------- ----
  Cefotetan             128-- \> 256                                      \> 256                                                \> 256   100   1-- \> 256          128      256      89
  Cefotaxime            \> 32                                             \> 32                                                 \> 32    100   1-- \> 32           \> 32    \> 32    98
  Ceftazidime           128-- \> 256                                      256                                                   \> 256   100   0.25-- \> 256       \> 256   \> 256   96
  Cefepime              128-- \> 256                                      \> 256                                                \> 256   100   0.25-- \> 256       \> 256   \> 256   93
  Aztreonam             \> 256                                            \> 256                                                \> 256   100   \< 0.125-- \> 256   \> 256   \> 256   93
  Ertapenem             \> 32                                             \> 32                                                 \> 32    100   1-- \> 32           \> 32    \> 32    96
  Imipenem              32-- \> 32                                        \> 32                                                 \> 32    100   0.5-- \> 32         4        16       69
  Meropenem             \> 32                                             \> 32                                                 \> 32    100   0.5-- \> 32         16       \> 32    96
  Amikacin              \> 256                                            \> 256                                                \> 256   100   2-- \> 256          \> 256   \> 256   84
  Ciprofloxacin         \> 32                                             \> 32                                                 \> 32    100   \< 0.125-- \> 32    \> 32    \> 32    93
  Tigecycline           0.25--2                                           0.5                                                   1        0     0.5--4              2        4        22
  Colistin              0.126--16                                         0.25                                                  0.5      8     0.125--32           0.5      4        11

Abbreviations: KPC, *Klebsiella pneumoniae* carbapenemase; OXA, oxacillinase; MIC, minimum inhibitory concentration; MIC~50~, minimum inhibitory concentration for 50% of isolates; MIC~90~, minimum inhibitory concentration for 90% of isolates; % R, % of resistance.
